Skip to main content
QuestionsResearchTagsGuidelinesLeaderboard
tachyDx Research Portal

Research tagged [neurology]

Every paper is generated from a real clinical discussion on tachyDx, peer-reviewed by verified physicians, and published with a unique TDX identifier. All contributors are credited.

DOIs registered viaCrossref
Published26Under ReviewFlagged
Clear filters

4 papers

TDX-2026-00020

DWI-FLAIR Mismatch and Large Vessel Occlusion in Wake-Up Stroke: A Synthesis of Expert Opinion and Evidence from a Clinical Case Discussion

Background: Wake-up stroke (WUS) presents a significant challenge in acute ischemic stroke management due to unknown symptom onset time, complicating eligibility for time-sensitive reperfusion therapies. Imaging-based selection, particularly diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR) mismatch, has expanded treatment windows for intravenous thrombolysis (IVT), while advanced perfusion imaging guides mechanical thrombectomy (MT) in large vessel occlusion (LVO). This paper synthesizes expert clinical decision-making in a complex WUS case with DWI-FLAIR mismatch and LVO, integrating current evidence. Methods: This academic paper formalizes a clinical Q&A discussion from the tachyDx platform, involving two verified stroke neurologists and receiving 96 community peer votes. The discussion centered on a 67-year-old female with WUS, left hemiplegia, NIHSS 14, right M1 occlusion, DWI-FLAIR mismatch, and a large penumbra on CT perfusion. Results: Both experts advocated for immediate bridging IVT followed by MT. Divergence arose in IVT dosing: one expert recommended standard 0.9 mg/kg alteplase, citing potential for maximum thrombolytic effect in LVO, while the other preferred 0.6 mg/kg, aligning with regional protocols and improved safety profiles. Both acknowledged the role of good collaterals in delaying FLAIR changes, supporting the validity of the DWI-FLAIR mismatch. The patient achieved TICI 2c reperfusion and significant neurological improvement. Conclusions: This case highlights the evolving consensus on aggressive reperfusion strategies for WUS with favorable imaging. It underscores the ongoing debate regarding optimal IVT dosing in the context of bridging therapy for LVO, emphasizing the need for individualized treatment guided by comprehensive imaging and patient-specific factors.

A physician-only Q&A platform where verified medical doctors share clinical knowledge, debate evidence, and build the knowledge base the world needs.

Powered by

Platform

  • Questions
  • Research
  • Tags
  • Guidelines
  • Leaderboard
  • Report a Bug

Ecosystem

  • Teams
  • Sponsors
  • Hiring
  • Publishing
  • CME
  • Data

Company

  • About
  • Support
  • Privacy Policy
  • Terms of Service
  • Contact

© 2026 Aethryva Deeptech Pvt Ltd. All rights reserved.

Crossref Member
2 contributors 96 votes 9 Apr 2026

TDX-2026-00010

Differential Diagnosis and Management of Neuroleptic Malignant Syndrome and Serotonin Syndrome in Polypharmacy: A Clinical Case and Community Consensus

Neuroleptic Malignant Syndrome (NMS) and Serotonin Syndrome (SS) represent life-threatening adverse drug reactions with significant clinical overlap, posing a considerable diagnostic challenge, particularly in patients receiving multiple psychotropic medications. This paper presents a detailed analysis of a 45-year-old male on haloperidol and fluoxetine who developed severe hyperthermia, rigidity, altered mental status, and elevated creatine phosphokinase (CPK), necessitating urgent differentiation and management. Through a community peer-reviewed clinical discussion involving two verified physicians and 59 peer votes, a consensus was reached on diagnostic criteria and therapeutic strategies. Key distinguishing features identified included the presence of lead-pipe rigidity and bradykinetic facies, a significantly elevated CPK level (12,400 U/L, peaking at 18,000 U/L), and a subacute onset over several days, which collectively favored a diagnosis of NMS. Management involved immediate discontinuation of all suspected agents, aggressive supportive care including intravenous hydration and cooling, and the initiation of dantrolene. The patient demonstrated clinical improvement with normalization of temperature and mental status, and resolution of renal dysfunction. This case highlights the critical importance of meticulous clinical assessment and a structured approach to management in complex neuroleptic- and serotonergic-induced toxicities, emphasizing the utility of specific pharmacological interventions tailored to the suspected syndrome while maintaining robust supportive care.

2 contributors 59 votes 6 Apr 2026

TDX-2026-00009

Management of Phenobarbital-Resistant Neonatal Seizures in Hypoxic-Ischemic Encephalopathy: A Community Peer-Reviewed Clinical Consensus

Background: Neonatal seizures, particularly in the context of hypoxic-ischemic encephalopathy (HIE), represent a significant neurological emergency. Despite phenobarbital being the established first-line anticonvulsant, a substantial proportion of neonates exhibit refractory seizures, necessitating the judicious selection of second-line agents. Optimal management strategies for these challenging cases, including appropriate antiepileptic drug (AED) dosing, electroencephalographic monitoring targets, and pharmacokinetic considerations during therapeutic hypothermia, remain areas of ongoing clinical discussion. Methods: This paper synthesizes a peer-reviewed clinical discussion initiated on the tachyDx platform. A clinical scenario involving a 3-day-old term neonate with HIE Grade II experiencing phenobarbital-resistant seizures during therapeutic hypothermia was presented. Two verified physician experts provided detailed responses, which subsequently garnered 49 community peer votes. Results: Levetiracetam was identified as the preferred second-line agent over phenytoin, citing its comparable efficacy to phenobarbital in some studies and a more favorable side effect profile in neonates. Recommended levetiracetam dosing included a 40-60 mg/kg intravenous load followed by 10-30 mg/kg/day maintenance in divided doses. Consensus indicated a goal of electrographic seizure freedom on amplitude-integrated electroencephalography (aEEG) if achievable without excessive sedation, with a threshold for escalating therapy defined as continuous seizure activity exceeding 50% of a 1-hour epoch. However, caution was advised against over-treatment of isolated, brief electrographic events. Therapeutic hypothermia was noted to reduce hepatic metabolism by approximately 25%, impacting phenobarbital levels, while levetiracetam, being primarily renally cleared, was less affected, though mild reductions in glomerular filtration rate were acknowledged. Conclusions: This expert consensus provides practical guidance for managing phenobarbital-resistant neonatal seizures in HIE. Levetiracetam emerges as a favored second-line option, with specific dosing and aEEG monitoring strategies outlined. The critical influence of therapeutic hypothermia on AED pharmacokinetics necessitates careful monitoring and dose adjustments. These findings underscore the importance of individualized, evidence-informed approaches to optimize neurodevelopmental outcomes.

2 contributors 49 votes 6 Apr 2026

TDX-2026-00003

Evidence-Based Framework for Refractory Status Epilepticus Management: A Community Peer-Reviewed Clinical Consensus

Background: Refractory status epilepticus (RSE) represents a neurological emergency associated with significant morbidity and mortality, characterized by persistent seizure activity despite the administration of adequate doses of at least two antiepileptic drugs, including a benzodiazepine. Optimal management strategies for RSE, particularly regarding continuous infusion agents, electroencephalographic targets, and the timing of etiologic investigations, remain subjects of ongoing clinical debate and require expert consensus. Methods: This paper synthesizes expert opinions derived from a structured, community peer-reviewed clinical discussion on the tachyDx platform. Three verified physicians, specializing in neurology and critical care, contributed to a case-based scenario of a 32-year-old female presenting with new-onset RSE. Their responses underwent peer evaluation by 106 community physicians. Results: Consensus emerged on several critical aspects of RSE management. Midazolam infusion was favored over propofol as a first-line continuous agent due to concerns regarding Propofol Infusion Syndrome (PRIS). The initial electroencephalographic target was seizure suppression, with escalation to burst-suppression reserved for persistent seizures. Infusions were typically maintained for 24-48 hours post-seizure cessation. Ketamine was identified as a valuable second-line continuous infusion. Early immunologic workup, particularly for anti-NMDA receptor encephalitis, was strongly recommended in new-onset RSE without clear etiology. Meticulous hemodynamic and electrolyte management was emphasized. Conclusions: The synthesized expert consensus provides a practical, evidence-informed framework for managing RSE, highlighting the importance of a multidisciplinary approach, careful agent selection, individualized electroencephalographic targets, and prompt etiologic investigation, especially for autoimmune causes.

3 contributors 106 votes 6 Apr 2026
Page 1 of 2Next →

Topics

Allpharmacology8critical-care7cardiology6emergency-medicine6oncology5pulmonology5nephrology4neurology4gastroenterology3immunology3hematology3surgery3infectious-disease3radiology2endocrinology2anesthesiology2hepatology2pediatrics2rheumatology2evidence-based-medicine1orthopedics1trauma1neonatology1psychiatry1internal-medicine1